AlphAIalphai — Financial news for AI agents
BenzingaNOV 263 min read$KALA

What Sparked KALA BIO's Nearly 38% Surge Overnight? - NovaBay Pharmaceuticals (AMEX:NBY), Kala Bio (NASDAQ:KALA)

KALA BIO Inc. ( NASDAQ:KALA ) jumped 37.87% to $0.88 in after-hours trading on Tuesday. Check out the current price of KALA stock here. According to Benzinga Pro data, the stock closed the regular session at $0.64, up 3.45%.

Original reporting
Benzinga · Mohd Haider
Published Nov 26, 2025, 5:34 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 26, 2025, 6:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
What Sparked KALA BIO's Nearly 38% Surge Overnight? - NovaBay Pharmaceuticals (AMEX:NBY), Kala Bio (NASDAQ:KALA) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$KALABullishMed
01

Why it matters

The sudden price movement could lead to increased volatility and trading volume, affecting liquidity and risk levels.

02

Market read

While the move is significant for KALA, its impact on the broader biotech sector and markets is limited without corroborating news.

03

What to watch

Lack of detailed news or fundamental catalysts raises concerns about the sustainability of the price increase.

Timing: short-term (next few days)

Background

KALA BIO's stock surged dramatically after-hours, possibly due to undisclosed news or speculative trading activity.

Company-level read

Ticker impact

$KALABullishMedium confidence
Context

High relevance due to significant overnight price surge and recent news coverage.

Expected impact

Potential continued upward momentum in the short term, with possible correction after the initial surge.

Evidence & confidence

The substantial overnight gain indicates strong buying interest, but without specific news details, the sustainability of the move is uncertain.

Market effects

Sector

The biotech sector may experience increased attention, but the impact is limited to KALA due to lack of broader sector movement.

Regional

Minimal regional impact, primarily affecting US-based biotech stocks.

Global

Low, as the news pertains to a specific company and sector.

Counterpoint

What could challenge this read

The surge may be a temporary spike driven by speculative trading, risking a swift reversal.

Key entities

  • Company
    KALA BIO Inc.

    A biotechnology company focusing on innovative therapies.

Read at source← All news

Related articles

AUG 28
$MAIRMedAI 8/10

Billionaire Tycoon Ernesto Bertarelli Buys $219 Million in Madison Air Solutions Shares. What Does This Mean for Investors?

Billionaire Ernesto Bertarelli indirectly purchased 8.8 million shares of Madison Air Solutions (MAIR) at $24.97 per share, totaling $219 million. The acquisition was made through K.C. Armada, LP, bringing his indirect ownership to 11% of the company. MAIR's stock closed at $28.51, a 14% premium over the purchase price. The company has a market cap of $14.3 billion and expects 18% revenue growth this fiscal year.

fool.com2 min
AUG 28
$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

investing.com2 min
AUG 28
$MSFTHigh

Prediction: Microsoft Could Be the Next $5 Trillion Stock

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

yahoo.com3 min
AUG 28
$LLYMedAI 9/10

FRI AM News: WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company; State joins lawsuit targeting Trump administration over family planning funding

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi

wisbusiness.com3 min